Reata Pharmaceuticals, Inc. (RETA) Expected to Earn Q3 2017 Earnings of ($0.41) Per Share
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) – Analysts at Leerink Swann issued their Q3 2017 earnings estimates for shares of Reata Pharmaceuticals in a research report issued to clients and investors on Wednesday. Leerink Swann analyst J. Schwartz anticipates that the company will post earnings of ($0.41) per share for the quarter. Leerink Swann has a “Outperform” rating and a $43.00 price target on the stock. Leerink Swann also issued estimates for Reata Pharmaceuticals’ Q4 2017 earnings at ($0.48) EPS, FY2017 earnings at ($1.73) EPS, FY2018 earnings at ($2.01) EPS, FY2019 earnings at ($1.95) EPS, FY2020 earnings at ($0.80) EPS and FY2021 earnings at $0.48 EPS.
Other research analysts have also issued research reports about the company. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $61.00 price objective (up previously from $55.00) on shares of Reata Pharmaceuticals in a research report on Wednesday, July 26th. Robert W. Baird restated an “outperform” rating and set a $47.00 price objective (up previously from $43.00) on shares of Reata Pharmaceuticals in a research report on Tuesday, July 25th. Piper Jaffray Companies boosted their price objective on Reata Pharmaceuticals from $53.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, July 24th. Zacks Investment Research lowered Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, July 18th. Finally, ValuEngine upgraded Reata Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 27th. Two investment analysts have rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Reata Pharmaceuticals has a consensus rating of “Buy” and an average price target of $51.63.
TRADEMARK VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Expected to Earn Q3 2017 Earnings of ($0.41) Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/09/15/reata-pharmaceuticals-inc-reta-expected-to-earn-q3-2017-earnings-of-0-41-per-share.html.
Shares of Reata Pharmaceuticals (RETA) opened at 30.48 on Friday. The stock’s 50 day moving average price is $28.61 and its 200 day moving average price is $26.85. The stock’s market cap is $795.62 million. Reata Pharmaceuticals has a 1-year low of $18.51 and a 1-year high of $41.60.
In other Reata Pharmaceuticals news, Director James Edward Bass bought 8,064 shares of the business’s stock in a transaction on Tuesday, August 1st. The shares were purchased at an average price of $31.00 per share, with a total value of $249,984.00. Following the purchase, the director now directly owns 67,411 shares of the company’s stock, valued at $2,089,741. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 62.40% of the company’s stock.
Institutional investors have recently made changes to their positions in the business. FMR LLC raised its stake in shares of Reata Pharmaceuticals by 74.4% in the 2nd quarter. FMR LLC now owns 414,491 shares of the company’s stock worth $13,114,000 after buying an additional 176,885 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Reata Pharmaceuticals by 109.6% in the 2nd quarter. Vanguard Group Inc. now owns 295,540 shares of the company’s stock worth $9,350,000 after buying an additional 154,515 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Reata Pharmaceuticals by 78.1% in the 2nd quarter. JPMorgan Chase & Co. now owns 232,562 shares of the company’s stock worth $7,359,000 after buying an additional 101,969 shares in the last quarter. RGT Capital Management Ltd. bought a new stake in shares of Reata Pharmaceuticals in the 1st quarter worth $1,347,000. Finally, King Luther Capital Management Corp bought a new stake in shares of Reata Pharmaceuticals in the 1st quarter worth $1,268,000. 21.85% of the stock is currently owned by hedge funds and other institutional investors.
Reata Pharmaceuticals Company Profile
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.